152 related articles for article (PubMed ID: 35606228)
1. Impact of diabetic retinopathy on prognosis of patients with heart failure with preserved ejection fraction.
Yang Y; Zhou Y; Cao Y; Dong Y; Liu C; Zhu W
Nutr Metab Cardiovasc Dis; 2022 Jul; 32(7):1711-1718. PubMed ID: 35606228
[TBL] [Abstract][Full Text] [Related]
2. Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients with Preserved Ejection Fraction: Evidence from the TOPCAT trial.
Zhu W; Cao Y; Ye M; Huang H; Wu Y; Ma J; Dong Y; Liu X; Liu C; Lip GYH
Thromb Haemost; 2023 Jan; 123(1):85-96. PubMed ID: 36037830
[TBL] [Abstract][Full Text] [Related]
3. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
4. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
5. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
[TBL] [Abstract][Full Text] [Related]
6. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
Zhu W; Wu Y; Zhou Y; Liang W; Xue R; Wu Z; Dong Y; Liu C
Cardiovasc Drugs Ther; 2020 Dec; 34(6):763-772. PubMed ID: 32583288
[TBL] [Abstract][Full Text] [Related]
7. Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction.
Tromp J; Lim SL; Tay WT; Teng TK; Chandramouli C; Ouwerkerk W; Wander GS; Sawhney JPS; Yap J; MacDonald MR; Ling LH; Sattar N; McMurray JJV; Richards AM; Anand I; Lam CSP;
Diabetes Care; 2019 Sep; 42(9):1792-1799. PubMed ID: 31292141
[TBL] [Abstract][Full Text] [Related]
8. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.
Sandesara PB; O'Neal WT; Kelli HM; Samman-Tahhan A; Hammadah M; Quyyumi AA; Sperling LS
Diabetes Care; 2018 Jan; 41(1):150-155. PubMed ID: 29051160
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
[TBL] [Abstract][Full Text] [Related]
12. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
[TBL] [Abstract][Full Text] [Related]
13. WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction.
Zhang X; Lv X; Wang N; Yu S; Si J; Zhang Y; Cai M; Liu Y
Int J Cardiol; 2023 Aug; 385():34-40. PubMed ID: 37257517
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
[TBL] [Abstract][Full Text] [Related]
15. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
[TBL] [Abstract][Full Text] [Related]
16. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
17. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
18. Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Rahimi G; Tecson KM; Elsaid O; McCullough PA
Am J Cardiol; 2021 Mar; 142():91-96. PubMed ID: 33279481
[TBL] [Abstract][Full Text] [Related]
19. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
